ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the Rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis - Lingor, Paul; Weber, Markus; Camu, William; Friede, Tim; Hilgers, Reinhard; Leha, Andreas; Neuwirth, Christoph; Günther, René; Benatar, Michael; Kuzma-Kozakiewicz, Magdalena; Bidner, Helen; Blankenstein, Christiane; et al. (Frontiers in neurology, 2019)
Members of the ROCK-ALS investigators: Shahram Attarian, Mathias Bähr, Matthias Boentert, Nathalie Braun, Philippe Corcia, Isabell Cordts, Marcus Deschauer, Thorsten Grehl, Julian Grosskreutz, Andreas Hermann, Josua Kuttler, Teresa Lengenfeldt, Fabian Maass, Thomas Meyer, Susanne Petri, Yvonne Remane, Jens Schmidt, Joachim Schuster, Marie-Hélène Soriani, Jeffrey Statland, Jochen Weishaupt, Daniel Zeller, Eirini Zielke